Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared to $186.99 million a year, beating the consensus of $65.78 million. Product sales of $38 million for the third quarter of 2024 were primarily related to U.
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi. Shares of the U.
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax falls after guidance cut on lower vaccine sales
Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 financials, cut its full-year revenue guidance, citing a gloomy sales outlook for its COVID-19 vaccine,
AOL2d
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...
Novavax Cuts FY24 Revenue View Below Market; Stock Drops In Pre-market - Update
Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast ...
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...
MarketWatch1d
Novavax Inc. stock underperforms Tuesday when compared to competitors
Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to ...
bovnews4d
Novavax Inc (NVAX) Stock: A Deeper Look at Its True Potential
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.91 which represents a decrease of $-0.27 or -2.94% from the prior close of $9.18. The stock opened at $9.25 and touched a low of ...
Business Insider2d
Novavax Resumes Phase 3 Vaccine Trials After FDA Hold
For a thorough assessment of NVAX stock, go to TipRanks’ Stock Analysis page. Trending Articles Novavax NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
bovnews6d
Novavax Inc (NVAX) Stock Sees Market Value Hit $1.47 billion: What Are the Implications?
On Thursday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.18 which represents a slight increase of $0.22 or 2.46% from the prior close of $8.96. The stock opened at $9.16 and ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...